Literature DB >> 20954819

Thyrotropin receptor-stimulating Graves' disease immunoglobulins induce hyaluronan synthesis by differentiated orbital fibroblasts from patients with Graves' ophthalmopathy not only via cyclic adenosine monophosphate signaling pathways.

Clementine J J van Zeijl1, Eric Fliers, Chris J van Koppen, Olga V Surovtseva, Marcel E de Gooyer, Maarten P Mourits, Wilmar M Wiersinga, André M M Miltenburg, Anita Boelen.   

Abstract

BACKGROUND: Both expression of the thyrotropin receptor (TSHR) and the production of hyaluronan (HA) by orbital fibroblasts (OF) have been proposed to be implicated in the pathogenesis of Graves' ophthalmopathy (GO). HA is synthesized by three types of HA synthase. We hypothesized that TSHR activation by recombinant human TSH (rhTSH) and TSHR-stimulating Graves' disease immunoglobulins (GD-IgGs) via induced cyclic adenosine monophosphate (cAMP) signaling increases HA synthesis in differentiated OF from GO patients.
METHODS: Cultured human OF, obtained during decompression surgery from 17 patients with severe GO, were stimulated in vitro to differentiate into adipocytes. Differentiation was evaluated by phase-contrast microscopy. The differentiated OF were stimulated by rhTSH or by TSHR-stimulating GD-IgG. We measured cAMP using a biochemical assay, HA synthase mRNA expression by quantitative polymerase chain reaction, and HA in the supernatant by enzyme-linked immunosorbent assay.
RESULTS: All differentiated OF cultures expressed higher levels of TSHR mRNA than nondifferentiated OF cultures. Stimulation by rhTSH induced a marked cAMP response in 11 of 12 differentiated OF cultures, but no measurable HA response in all but one differentiated OF cultures. By contrast, stimulation by GD-IgG induced a moderate cAMP response in a number of differentiated OF cultures, but a marked HA response in the majority of differentiated OF cultures.
CONCLUSION: Stimulation of differentiated OF by GD-IgG, but not by rhTSH, induces HA synthesis in the majority of patients, suggesting that in most patients TSHR-mediated cAMP signaling does not play a pivotal role in GD-IgG-induced HA synthesis in differentiated OF cultures.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20954819     DOI: 10.1089/thy.2010.0123

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  24 in total

1.  Fibroblasts expressing the thyrotropin receptor overarch thyroid and orbit in Graves' disease.

Authors:  Terry J Smith; Dolly A Padovani-Claudio; Ying Lu; Nupur Raychaudhuri; Roshini Fernando; Stephen Atkins; Erin F Gillespie; Andrew G Gianoukakis; Barbra S Miller; Paul G Gauger; Gerard M Doherty; Raymond S Douglas
Journal:  J Clin Endocrinol Metab       Date:  2011-09-28       Impact factor: 5.958

2.  Mechanism of action of a nanomolar potent, allosteric antagonist of the thyroid-stimulating hormone receptor.

Authors:  Chris J van Koppen; Marcel E de Gooyer; Willem-Jan Karstens; Ralf Plate; Paolo G M Conti; Tanja A E van Achterberg; Monique G A van Amstel; Jolanda H G M Brands; Jesse Wat; Rob J W Berg; J Robert D Lane; Andre M M Miltenburg; C Marco Timmers
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

3.  Skin fibrosis correlates with circulating thyrotropin levels in systemic sclerosis: translational association with Hashimoto's thyroiditis.

Authors:  Gian Luca Bagnato; William Neal Roberts; Alessia Fiorenza; Chiara Arcuri; Rosaria Certo; Francesco Trimarchi; Rosaria Maddalena Ruggeri; Gian Filippo Bagnato
Journal:  Endocrine       Date:  2015-05-21       Impact factor: 3.633

Review 4.  The evaluation and treatment of graves ophthalmopathy.

Authors:  Marius N Stan; James A Garrity; Rebecca S Bahn
Journal:  Med Clin North Am       Date:  2012-02-22       Impact factor: 5.456

5.  Is IGF-I receptor a target for autoantibody generation in Graves' disease?

Authors:  Terry J Smith
Journal:  J Clin Endocrinol Metab       Date:  2013-02       Impact factor: 5.958

6.  Is Recombinant Human TSH a Trigger for Graves' Orbitopathy?

Authors:  C Daumerie; A Boschi; P Perros
Journal:  Eur Thyroid J       Date:  2012-06-07

7.  Safety of total thyroid ablation in patients with Graves' orbitopathy.

Authors:  M Moleti; G Sturniolo; F Vermiglio
Journal:  J Endocrinol Invest       Date:  2016-05-20       Impact factor: 4.256

8.  A small molecule antagonist inhibits thyrotropin receptor antibody-induced orbital fibroblast functions involved in the pathogenesis of Graves ophthalmopathy.

Authors:  Adina F Turcu; Seema Kumar; Susanne Neumann; Michael Coenen; Seethalakshmi Iyer; Pamela Chiriboga; Marvin C Gershengorn; Rebecca S Bahn
Journal:  J Clin Endocrinol Metab       Date:  2013-03-12       Impact factor: 5.958

Review 9.  Platelet-derived growth factor: a key factor in the pathogenesis of graves' ophthalmopathy and potential target for treatment.

Authors:  Sita Virakul; Leendert van Steensel; Virgil A S H Dalm; Dion Paridaens; P Martin van Hagen; Willem A Dik
Journal:  Eur Thyroid J       Date:  2014-12-06

10.  Forkhead Transcription Factor FOXO1 Is Regulated by Both a Stimulatory Thyrotropin Receptor Antibody and Insulin-Like Growth Factor-1 in Orbital Fibroblasts from Patients with Graves' Ophthalmopathy.

Authors:  Seema Kumar; Michael Coenen; Seethalakshmi Iyer; Rebecca S Bahn
Journal:  Thyroid       Date:  2015-08-19       Impact factor: 6.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.